| | March 20169CIOReviewspeeding the discovery and development of potential therapies for patients in need.3. Digital and IoT Serving Patients and PhysiciansPfizer is at the forefront of embracing emerging technologies, open source, cloud computing and advanced interactive digital technologies to engage patients and physicians in a meaningful way that goes "beyond the pill" to provide better outcomes. Whether it is in leveraging mobile devices and novel apps to improve clinical trial data collection or in providing custom wearables to track pain levels to assist with physician conversations on dosing, Pfizer is focused on having insights drive the most meaningful features and utilizing technologies that are fit for purpose. An example is how Pfizer is partnering with the American Lung Association on a mission to support smokers' attempts at a healthier life by utilizing technology to overcome common barriers to a successful quit attempt. The Quitters Circle combines a mobile app, a wearable, and a rich social media experience to provide quitters and their targeted support network with the tools they need to quit "for good", including tracking tools, informative content, support triggers, Quitspiration, and ready access to physicians and telemedicine. Pfizer understands that the world we live in and the technologies at our fingertips are ever evolving, and through the creation of Pfizer's Digital, Mobile, and Emerging Technologies Centers of Excellence, Pfizer has committed to ensuring their organization will as well.Finally, Pfizer has begun using actigraphy data­data gener-ated from sensors­to understand patient response to medicines. In effect, the "internet of things" becomes the "internet of pa-tients" as FitBit-like sensors are used in our trials to continuously monitor patients to understand if Pfizer's medicine is controlling their tremors, or if they are able to sleep at night. This type of data allows Pfizer to demon-strate an improve-ment in a patient's quality of life in a way that wasn't possible with tradi-tional measurement models.4. Partnering for Innovation--Bringing the Best Medical and Scientific Minds TogetherPfizer engages in hundreds of formal partnerships, actively building and cultivating relationships with top centers of medical and scientific innovation in academia, clinical, medical, and hospital institutions around the globe. Solving the world's toughest medical challenges requires the ability to quickly and securely collaborate with these partners­crucial for advancing the development of innovative patient therapies while protecting Pfizer's intellectual property.Business Technology plays a key role in enabling Pfizer's open innovation model through the use of scalable, agile and secure collaboration technologies. With sophisticated technology playbooks, processes and tools at their fingertips, it is now possible to establish secure connectivity and collaboration environments regardless of deal complexity in a matter of hours, rather than days or months, making Pfizer a respected "Partner of Choice". 5. Thought Leadership in Business TechnologyBecause technology is embedded and acknowledged in every facet of science and business operations, Business Technology colleagues are accountable for demonstrating effective thought leadership­now a critical capability and a key factor in talent selection and advancement. Through effective thought leadership, successful IT organizations are identified as having more than just a "seat at the table"­but as being "front and center" in every facet of our business.The Formula Five is a major driving force toward achieving Pfizer's mission. The effective use of the clinical cloud, precision analytics, digital and emerging technologies, agile and secure collaborations, and the thought leadership to effectively align and connect these focus areas to business strategy, will all work together toward success in Biotechnology at Pfizer.Business Technology has developed a scalable cloud architecture leveraging best-in-class agile technologies for clinical data management and analytics"
< Page 8 | Page 10 >